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Abstract
Background: Cellular and animal studies implicate multiple roles of amylin in regulating insulin action, glucose and lipid
metabolisms. However, the role of amylin in obesity related metabolic disorders has not been thoroughly investigated in
humans. Therefore, we aimed to evaluate the distribution of circulating amylin and its association with metabolic syndrome
(MetS) and explore if this association is influenced by obesity, inflammatory markers or insulin resistance in apparently
healthy Chinese.
Methods: A population-based sample of 1,011 Chinese men and women aged 35–54 years was employed to measure
plasma amylin, inflammatory markers (C-reactive protein [CRP] and interleukin-6 [IL-6]), insulin, glucose and lipid profiles.
MetS was defined according to the updated National Cholesterol Education Program Adult Treatment Panel III criteria for
Asian-Americans.
Results: Plasma amylin concentrations were higher in overweight/obese participants than normal-weight counterparts
(P,0.001) without sex difference. Circulating amylin was positively associated with CRP, IL-6, BMI, waist circumference,
blood pressure, fasting glucose, insulin, amylin/insulin ratio, HOMA-IR, LDL cholesterol and triglycerides, while negatively
associated with HDL cholesterol (all P,0.001). After multiple adjustments, the risk of MetS was significantly higher (odds
ratio 3.71; 95% confidence interval: 2.53 to 5.46) comparing the highest with the lowest amylin quartile. The association
remained significant even further controlling for BMI, inflammatory markers, insulin or HOMA-IR.
Conclusions: Our study suggests that amylin is strongly associated with inflammatory markers and MetS. The amylin-MetS
association is independent of established risk factors of MetS, including obesity, inflammatory markers and insulin
resistance. The causal role of hyperamylinemia in the development of MetS needs to be confirmed prospectively.
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Introduction
Amylin, also named islet amyloid polypeptide (IAPP), is a 37
amino acid polypeptide initially isolated from amyloid deposit in
pancreatic islets of type 2 diabetes patients [1,2]. Amylin is co-
secreted with insulin by b-cells in response to stimulation of
glucose, free fatty acids and food intake [3–5]. Amylin is an
important player in the control of energy balance [6]. Amylin
inhibits food intake by promoting meal-ending satiation, possibly
through stimulation of its receptor in the area postrema [7]. The
nucleus of the solitary tract and the lateral parabrachial nucleus
seem to be also involved in the inhibitory effect of amylin on food
intake [6]. Amylin increases energy expenditure after peripheral
and central administration in animals [6]. Chronic infusion of
amylin into the brain reduces body weight gain and adiposity,
while chronic infusion of an amylin receptor antagonist into the
brain increases body adiposity [6,8]. Amylin was found in vitro to
inhibit both basal and insulin stimulated glycogenesis in rat
skeleton muscle [9] and also to impair glucose disposal in liver cells
[10]. Moreover, an animal study also showed that amylin could
suppress insulin secretion by enhancing b-cell apoptosis, which
consequently induced hepatic and extrahepatic insulin resistance
and glucose dysregulation in human IAPP transgenic rats [11].
Infusion of amylin in dog also induced peripheral insulin resistance
[12]. Elevated levels of amylin were observed in obese children
[13] and obese adults with impaired glucose tolerance or type 2
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preterm neonates with feed intolerance [15,16]. However, the
pathophysiological role(s) of amylin in human metabolic diseases
have not been studied in large-scale populations.
Metabolic syndrome (MetS), an aggregation of metabolic
abnormalities comprising central obesity, dyslipidemia, elevated
blood pressure and hyperglycemia, is a generally acknowledged
precursor of type 2 diabetes and cardiovascular disease (CVD)
[17]. A recent meta-analysis showed that MetS is associated with a
2-fold increase in risk of CVD, CVD mortality, and stroke [18].
Owing to excess caloric intake and a sedentary lifestyle, global
epidemic trends of obesity and MetS have become one of the
public health challenges not only in Western countries [19] but
also in Asian societies like China [20]. It was estimated that
approximate 38% of men and 33% of women aged 35–74 years in
China had at least one component of MetS, and 14% of men and
18% of women had three or more components of MetS [20].
During past decades, accumulating evidence has highlighted
chronic low-grade inflammation as one of the important
mechanisms involving in pathogenesis of obesity and related
metabolic disorders such as metabolic syndrome, type 2 diabetes
and cardiovascular diseases [21]. However, evidence is scarce
about the relationships between amylin, inflammatory status and
metabolic diseases. Therefore, we aimed to investigate the
distribution of plasma amylin and its associations with inflamma-
tory markers and MetS in 1011 apparently healthy Chinese adults.
We also examined whether the amylin-MetS association is
independent of well established risk factors including obesity,
inflammatory markers and insulin resistance.
Materials and Methods
Ethics statements
The study was approved by the Institutional Review Board of
the Institute for Nutritional Sciences, Chinese Academy of
Sciences (Permit No. E-2007-01) and a written informed consent
was obtained from each participant.
Study design
The study design and recruitment of participants have been
described in detail elsewhere [22]. In brief, the study population
was from the Gut Microbiota and Obesity Study, a population-
based case-control study among noninstitutionalized residents
aged 35–54 years in Shanghai, China. Two urban districts (Luwan
and Zhabei) were chosen to represent people with high and low
socioeconomic status in urban Shanghai. Eligible candidates were
apparently healthy adults who have lived in Shanghai for at least
10 years. Five hundred pairs of age- and sex-matched subjects
(overweight/obesity) and control subjects (normal-weight) were
planned to be recruited. Finally, a total of 1,059 eligible
participants were successfully recruited from November 2007 to
January 2008. Normal weight and overweight/obesity were
defined as 18#BMI,24.0 kg/m
2 and BMI$24.0 kg/m
2, respec-
tively, according to the recommendation by the Working Group
on Obesity in China [23–25]. The BMI range is 18.0 to 23.9 kg/
m
2 for normal weight and 24.0 to 40.5 kg/m
2 for overweight/
obesity.
Face to face interviews were conducted by trained physicians or
public health workers from the local Centers for Disease Control
and Prevention, and also from community clinics. Information of
demographic variables, health status and behaviors, physical
activity and educational attainment were obtained through a
standardized questionnaire. Family history of chronic diseases was
positive if one of the parents or siblings had coronary heart disease,
stroke, or type 2 diabetes. Body weight, height, waist circumfer-
ence, and blood pressure were measured using a standardized
protocol [22].
Laboratory measurements
Overnight fasting venous blood samples were collected by tubes
containing EDTA, centrifuged at 4uC and stored at 280uC until
laboratory analyses. Laboratory assays for total cholesterol, high-
density lipoprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol, triglycerides, glucose, C-reactive protein (CRP),
interleukin 6 (IL-6), and insulin were described previously [22].
The insulin resistance index (homeostasis model assessment of
insulin resistance, HOMA-IR) was calculated according to
updated homeostasis model assessment methods (http://www.
dtu.ox.ac.uk/). Amylin concentrations were measured by a
monoclonal antibody-based sandwich immunoassay (Human
amylin total ELISA kit, Millipore, Billerica, MA). The assay has
a sensitivity of 1 pmol/l with measurable concentrations within 1–
100 pmol/l. All procedures followed the manufacture’s instruc-
tions with two quality controls in expected ranges for each assay.
The inter assay-CV was 10% for one of quality controls and was
7.3% for the other one. Every tenth sample was duplicated on the
same plate and the average intra-assay CV for amylin was 7.6%.
Forty-eight persons with limited plasma samples were excluded
and data from 1011 (527 overweight/obese and 484 normal-
weight) participants were available for amylin analyses.
Definition of Mets
MetS was defined based on the updated National Cholesterol
Education Program Adult Treatment Panel III criteria for Asian-
Americans [17], including at least three of the following
components: 1) waist circumference $90 cm in men or $80 cm
in women; 2) triglycerides $1.7 mmol/l; 3) HDL cholesterol
,1.03 mmol/l in men, or ,1.30 mmol/l in women; 4) blood
pressure $130/85 mm Hg, or current use of antihypertensive
medications; and 5) fasting plasma glucose $5.6 mmol/l.
Statistical analyses
Normally distributed variables were expressed as mean 6
standard deviation (SD), while variables with a skewed distribu-
tion, including amylin, insulin, HOMA-IR, amylin/insulin ratio,
triglycerides, CRP and IL-6, were reported as geometric mean
(95% confidence interval). Amylin was log transformed to
approximate normality before statistical analyses. Categorical
variables were represented by frequency and percentage. Analysis
of covariance was used to calculate amylin concentrations
according to sex, age and BMI. Continuous characteristics across
amylin quartiles were compared using analysis of covariance,
whereas categorical characteristics across amylin quartiles were
compared using logistic regression model. Medians of each amylin
quartile were included as an independent variable for trend test.
Spearman partial correlation coefficients of amylin with metabolic
parameters and inflammatory markers were calculated in the
whole sample and subgroups. Multivariate logistic regression
models were applied to evaluate the adjusted odds ratios (ORs) for
MetS and its components according to the amylin quartiles.
Potential confounders were carefully controlled, including age, sex,
lifestyle factors, educational attainment, family history of chronic
diseases, and inflammatory markers. Potential interactions be-
tween BMI, inflammatory markers, insulin, HOMA-IR and
amylin were also examined. All statistical analyses were performed
with Stata 9.2. (College Station, TX, USA) and considered
statistically significant when 2-sided P,0.05.
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Distribution of amylin concentrations and characteristics
of participants
As shown in Table 1, geometric means of amylin were
significantly higher in older (aged $45 years) and overweight/
obese participants than their younger (6.85 vs. 6.57 pmol/l,
P=0.030) and normal weight counterparts (7.01 vs. 6.46 pmol/l,
P,0.001). When participants were characterized according to
amylin quartiles (Table 2), persons in the higher amylin quartile
had significantly higher levels of BMI, waist circumference, blood
pressure, fasting glucose, insulin, HOMA-IR, amylin/insulin ratio,
total and LDL cholesterol, triglycerides, but lower HDL
cholesterol concentrations (all P,0.001) compared with those in
the lower quartile. Moreover, plasma CRP and IL-6 also elevated
along with increased amylin quartiles (both P,0.001). We also
characterized the participants according to BMI quartiles, and
found that plasma amylin concentrations increased gradually
according to the quartile of BMI, the geometric means (95%
confidence interval [CI]) is 6.21 (5.99–6.44), 6.65(6.40–6.90), 6.84
(6.59–7.10) and 7.20 (6.96–7.46) pmol/l, respectively (P,0.001 for
trend).
Correlations of amylin concentrations with metabolic
parameters and inflammatory markers
Amylin was positively correlated with BMI, waist circumfer-
ence, blood pressure, fasting glucose, insulin, HOMA-IR, total
cholesterol, LDL-cholesterol, triglycerides, inflammatory markers
of CRP and IL-6, while, negatively correlated with plasma HDL-
cholesterol (Table 3, all P,0.001), after adjustment for age and
sex. Among all the metabolic parameters, amylin showed the
strongest correlation with insulin and HOMA-IR. In stratified
analyses, the correlations were generally stronger in overweight/
obese and male participants than in their normal-weight and
female peers.
Associations of amylin with metabolic syndrome and its
components
The prevalence of MetS progressively increased from 25.8% to
57.3% across amylin quartiles (Table 4). The severity of MetS,
indicated as #1, 2, 3 and $4 components, also increased
gradually across amylin quartiles (Figure 1). Table 4 (model 2)
showed that, compared with the lowest quartile of amylin, the
ORs in the highest quartile were 3.71 (95% CI: 2.53–5.46) for
MetS, 2.72 (1.88–3.93) for central obesity, 1.66 (1.14–2.41) for
elevated blood pressure, 1.88 (1.28–2.76) for hyperglycemia, 5.55
(3.58–8.61) for hypertriglyceridemia, and 2.56 (1.75–3.76) for low
HDL cholesterol (P,0.001 for trend for the overall risk of MetS
and most of the features except elevated blood pressure with P for
trend=0.002). Further adjustment for BMI and inflammatory
markers (model 4) only slightly reduced the magnitude of the
association of amylin with MetS (with an OR of 2.41, 95% CI:
1.46–3.97). Although further adjustment of insulin based on model
2 decrease the magnitude of the amylin-MetS association (with an
OR of 1.85, 95% CI: 1.21–2.85), the association of amylin with
MetS is still statistically significant (P=0.001 for trend). These
results suggest that amylin is associated with MetS independent of
obesity, inflammatory markers or insulin.
In joint classification analyses, rising amylin was associated with
approximately 2–5 fold higher risk of MetS in the individuals with
normal-weight (OR=2.6 [95% CI: 1.4–4.7] for Q4 vs. OR=1
[reference group], Figure 2A) and low inflammatory status
indicated as in the lowest quartile of CRP (OR=2.2 [95% CI:
0.7–7.4] for Q4 vs. OR=1.0 for Q1, Figure 2B), IL-6 (OR=4.9
[95% CI: 1.6–15.6] for Q4 vs. OR=1.0 for Q1, Figure 2C),
insulin (OR=2.1 [95% CI: 0.7–6.2] for Q4 vs. OR=1.0 for Q1,
Fig. 2D), and HOMA-IR (OR=1.9 [95% CI: 0.6–6.0] for Q4 vs.
OR=1.0 for Q1 Fig. 2E). However, the risk of MetS was more
pronounced among the participants who were overweight/obese
(OR=23.6 [95% CI: 12.9–43.1] for Q4 vs. OR=5.9 [95% CI:
3.3–10.5] for Q1) or in the highest quartile of plasma CRP
(OR=37.9 [95% CI: 14.1–101.8] for Q4 vs. OR=13.0 [95% CI:
4.6–36.5] for Q1), IL-6 (OR=35.9 [95% CI: 12.5–102.9] for Q4
vs. OR=8.3 [95% CI: 2.9–23.8] for Q1), insulin (OR=42.8 [95%
CI: 18.7–97.6] for Q4 vs. OR=11.5 [95% CI: 4.2–31.9] for Q1)
and HOMA-IR (OR=46.1 [95% CI: 20.0–106.1] for Q4 vs.
OR=16.7 [95% CI: 5.9–47.3] for Q1) in combination with
elevated circulating amylin. No significant interactions were
observed between amylin, obesity, inflammatory status and insulin
resistance on the risk of MetS (P.0.05 for all interaction tests).
Discussion
In this study, we found that elevated amylin concentrations were
significantly correlated with inflammatory status and unfavorable
metabolic traits. The strong positive association between amylin
and the risk of MetS was independent of the well established risk
factors, including obesity, inflammatory markers (CRP and IL-6)
and insulin resistance in apparently healthy Chinese population.
Few studies have examined the distribution of circulating
amylin in a large population. Previously, Reinehr et al reported
that serum amylin of 37 obese children was significantly higher
than that in 16 health lean children, but was not correlated with
age, sex and BMI [13]. Obese persons with/without impaired
glucose tolerance were found to have increased circulating amylin
[13,14,26,27] and obese individuals also tended to have higher
amylin response toward glucose load compared with non-obese
individuals [27]. With a relatively large sample, our data showed
that increased amylin concentrations across quartiles were
associated with not only advanced age and higher BMI, but also
Table 1. Amylin concentrations according to sex, age and
obesity status (pmol/l)
a.
n
Geometric mean
(95% confidence
interval) P value
Sex
b 0.121
Male 370 6.85 (6.64–7.06)
Female 641 6.64 (6.49–6.80)
Age
c 0.030
,45 years 395 6.57 (6.38–6.77)
$45 years 616 6.85 (6.69–7.02)
Obesity status
d ,0.001
Normal weight 484 6.46 (6.29–6.64)
Overweight/Obese 527 7.01 (6.83–7.19)
aGeometric means of amylin concentrations were compared using general
linear models (n=1011).
bAdjustment for BMI and age.
cAdjustment for sex and BMI.
dAdjustment for age and sex.
doi:10.1371/journal.pone.0024815.t001
Amylin and Metabolic Syndrome in Chinese
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24815unfavorable metabolic and inflammatory profiles (Table 2). In
general, the correlations were stronger in overweight/obese
participants than their normal-weight counterparts, particularly
in the case of insulin, HOMA-IR and triglycerides. However, the
mechanistic linkage between elevated amylin levels and obesity
related metabolic disorders has not been fully understood thus far.
Indeed, data from a weight loss intervention in obese children
suggested that changing of amylin levels was correlated with
altered insulin rather than change of BMI or percentage of body
fat [13].
One of the major findings of our current study is that we
discovered a strong association between plasma amylin and the
risk of MetS. Accumulating evidence, mainly from cellular and
animal studies, suggested that amylin plays important roles in
regulating food intake, insulin action and energy homeostasis, as
well as glucose and lipid metabolisms. Moreover, adverse effects of
increased amylin levels on metabolic abnormalities such as insulin
resistance or type 2 diabetes, have been indicated by some of
human studies [13,14]. However, little is known whether high
circulating amylin is an independent risk factor for MetS, a
preclinical condition associated with a 2-fold increase in risk of
CVD, CVD mortality, and stroke [18]. In this study, we found
that elevated amylin per se is associated with higher risk of MetS
even in normal weight persons, despite the fact that the MetS risk
was pronounced in overweight/obese participants (Figure 2A).
Obesity is a well established risk factor of MetS [28–30].
Adjustments for BMI in combining other potential confounders,
however, yielded only a minor reduction on the risk of MetS across
amylin quartiles (Table 4). Thus, the amylin-MetS association in
the current study apparently could not mainly be attributed to
obesity. Hyperinsulinemia associated with the insulin resistance of
obesity is also a defining marker of MetS. Our present study
showed that amylin and insulin were both elevated in obesity and
insulin resistance, which is consistent with previous reports
Table 2. Characteristics of participants according to amylin quartiles (n=1011)
a.
Variables Q1 Q2 Q3 Q4 P for trend
n (case/control) 252 (101/151) 253 (129/124) 253 (132/121) 253 (165/88)
Amylin (pmol/l) 4.71 (4.61–4.82) 6.24 (6.20–6.27) 7.21 (7.18–7.25) 9.59 (9.28–9.90) ,0.001
Age (years)
b 45.2 (5.5) 45.5 (5.5) 46.0 (5.5) 46.8 (5.1) ,0.001
Male, n (%)
b 94 (37.3) 83 (32.8) 88 (34.8) 105 (41.5) 0.242
Education, n (%) 0.994
0–9 years 68 (27.0) 67 (26.5) 73 (28.9) 68 (26.9)
10–12 years 129 (51.2) 129 (51.0) 129 (51.0) 137 (54.2)
$13 years 55 (21.8) 57 (22.5) 51 (20.2) 48 (19.0)
Current smoker, n (%) 59 (23.4) 54 (21.3) 57 (22.5) 74 (29.3) 0.271
Alcohol drinker, n (%) 111 (44.1) 74 (29.3) 83 (32.8) 96 (37.9) 0.083
Physical activity, n (%) 0.471
Low 13 (5.2) 28 (11.1) 23 (9.1) 32 (12.7)
Moderate 158 (62.7) 147 (58.1) 145 (57.3) 136 (53.8)
High 81 (32.1) 78 (30.8) 85 (33.6) 85 (33.6)
Family history of coronary heart disease,
stroke and diabetes, n (%)
103 (40.9) 98 (38.7) 101 (39.9) 101 (39.9) 0.693
Metabolic syndrome, n (%) 65 (25.8) 83 (32.8) 119 (47.0) 145 (57.3) ,0.001
BMI (kg/m
2) 23.4 (3.7) 24.2 (3.8) 24.9 (4.2) 25.8 (4.1) ,0.001
Waist circumference (cm) 81.5 (10.5) 82.9 (10.3) 85.3 (11.1) 89.0 (11.2) ,0.001
SBP (mm Hg) 121.7 (15.5) 122.1 (16.0) 126.7 (18.9) 128.1 (18.7) ,0.001
DBP (mm Hg) 76.9 (10.9) 78.2 (11.3) 80.5 (12.0) 81.7 (11.6) ,0.001
Fasting glucose (mmol/l) 5.8 (1.0) 6.0 (1.5) 6.1 (1.3) 6.3 (1.4) ,0.001
Insulin (mU/ml) 7.46 (7.03–7.92) 8.43 (7.88–9.01) 9.52 (8.97–10.11) 11.80 (11.05–12.61) ,0.001
HOMA-IR 0.87 (0.82–0.92) 0.98 (0.92–1.05) 1.11 (1.05–1.18) 1.38 (1.29–1.48) ,0.001
Amylin/insulin 0.09 (0.09–0.10) 0.11 (0.10–0.11) 0.11 (0.10–0.12) 0.12 (0.11–0.13) ,0.001
Total cholesterol (mmol/l) 5.0 (1.0) 5.1 (1.2) 5.4 (1.2) 5.4 (1.1) ,0.001
LDL cholesterol (mmol/l) 3.1 (0.8) 3.2 (1.0) 3.4 (1.0) 3.4 (0.9) ,0.001
HDL cholesterol (mmol/l) 1.5 (0.4) 1.4 (0.4) 1.4 (0.4) 1.3 (0.4) ,0.001
Triglycerides (mmol/l) 1.01 (0.95–1.07) 1.10 (1.03–1.18) 1.36 (1.26–1.46) 1.70 (1.57–1.84) ,0.001
CRP (mg/l) 0.74 (0.66–0.82) 0.83 (0.74–0.94) 1.00 (0.88–1.13) 1.17 (1.04–1.31) ,0.001
IL-6 (pg/ml) 1.33 (1.23–1.43) 1.27 (1.17–1.37) 1.45 (1.34–1.56) 1.63 (1.50–1.76) ,0.001
aData are arithmetic mean (SD) or geometric mean (95% confidence interval) if not specified. Percentages may not sum to 100 because of rounding. P for trend was
calculated after adjustment for age and sex.
bNot adjusted for itself.
doi:10.1371/journal.pone.0024815.t002
Amylin and Metabolic Syndrome in Chinese
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24815[13,14,26,27]. In addition, we found that amylin was associated
with MetS independent of hyperinsulinemia/insulin resistance.
Although the secretion of amylin and insulin is generally parallel
under physiological conditions, these two hormones are differently
regulated under certain circumstances. High glucose increases the
relative amount of amylin to insulin secretion from islets isolated
from dexamethasone- or glucose-treated rats in comparison with
islets isolated from fed and fasted rats [31]. Increased storage and
secretion of amylin relative to insulin has been reported in
spontaneously diabetic GK rats [32]. We found that participants
in the higher amylin quartile had higher amylin/insulin ratio and
higher risk of MetS, supporting the involvement of amylin in MetS
independent of insulin.
Another noteworthy finding in our study was that we observed a
significantly positive correlation between amylin and inflammatory
markers (CRP and IL-6) (Table 3). Low-grade inflammation is one
of the widely accepted key mechanisms related to obesity, insulin
resistance, type 2 diabetes and cardiovascular diseases, the
conditions often coexisted with hyperamylinemia. However, direct
evidence was scarce regarding the relationship between amylin
and inflammation. In our recent in vitro study, we observed that
tumor necrosis factor- a (TNF-a), a proinflammatory cytokine
elevated in obesity and insulin resistance, could induce amylin
gene expression in murine pancreatic b-cells and islets, and also
could activate human amylin promoter through multiple signaling
pathways [33]. Masters et al. [34] recently reported that amylin
triggered the NLRP3 inflammasome and generated mature IL-1b,
an important inflammatory mediator in type 2 diabetes, in
macrophages. Mice transgenic for human amylin had more IL-1b
in pancreatic islets, which localized together with amyloid and
macrophages. While it is still waiting to be verified whether the
findings from the in vitro and animal studies are biologically
relevant to humans, our data, however, showed that elevated
amylin was significantly correlated with increased plasma CRP
and IL-6. Interestingly, like in the case of obesity and insulin
resistance, the effect of CRP and IL-6 on the amylin-MetS
association was rather minor (Table 4). Together, this data again
suggests that amylin might independently promote metabolic
disorders through the mechanism(s) other than inflammatory
signaling pathway.
In the present study, we also documented that increased circulating
amylin was significantly associated with the severity (Figure 1) and
each component of MetS (Table 4). Interestingly, the association
between amylinand hypertriglyceridemia wasparticularly strong and
also independent of BMI, a well recognized risk factor for
hypertriglyceridemia [35], whereas the associations between amylin
and the rest of the MetS components were largely explained by BMI
(Table 4). Previously, a positive correlation between amylin and
triglycerides was reported based on a study of 53 children [13].
However, it remains controversial whether elevated amylin directly
or indirectly induce dyslipidemia or vice versa.F o ri n s t a n c e ,S m i t ha n d
coworkers reported that a bolus injection or infusion with amylin
significantly raised total plasma triglyceride levels and reduced
clearance of TG-rich lipoproteins by about 45% [36]. In another
study, Ye et al showed that amylin infusion in rats increased not only
circulating levels of non-esterified fatty acids and glycerol, but also
hepatic triglyceride content [37]. On the other hand, we found that
acute treatment with dietary fatty acids could enhance amylin
expression and secretion in murine pancreatic b cells [4], as well as
stimulate human amylin promoter activation. Furthermore, acutely
fed mice with high-lipid contained diet could raise plasma levels of
fatty acid, amylin and insulin in a temporal manner, implicating fatty
acid might play a critical role in inducing amylin release [4]. The
discrepancies might be due to inter-species variations of animal
models, different protocols and doses used among studies. Nonethe-
less, long-term studies, especially human studies, are merited to prove
the observations from acute animal studies and also to identify
mechanism(s) linking between hyperamylinemia and dyslipidemia.
Toourknowledge,thisisthe firststudytoevaluatetheassociation
between amylin levels and the risk of MetS in a relatively large-scale
population. Admittedly, due to the cross-sectional nature of current
study, we can not establish a causal association of amylin with MetS
Table 3. Partial spearman correlation coefficients of amylin with metabolic parameters and inflammatory markers.
Total
a
(n=1011)
Normal weight
a
(n=484)
Overweight/obese
a
(n=527)
Male
b
(n=370)
Female
b
(n=641)
rP value rP value rP value rP value rP value
BMI 0.21 ,0.001 0.12 0.007 0.18 ,0.001 0.29 ,0.001 0.17 ,0.001
Waist circumference 0.24 ,0.001 0.18 ,0.001 0.20 ,0.001 0.34 ,0.001 0.18 ,0.001
SBP 0.13 ,0.001 0.05 0.229 0.08 0.062 0.19 ,0.001 0.08 0.044
DBP 0.14 ,0.001 0.07 0.131 0.09 0.042 0.19 ,0.001 0.11 0.007
Fasting glucose 0.15 ,0.001 0.10 0.027 0.16 ,0.001 0.17 0.001 0.14 ,0.001
Insulin 0.33 ,0.001 0.20 ,0.001 0.38 ,0.001 0.39 ,0.001 0.28 ,0.001
HOMA-IR 0.33 ,0.001 0.21 ,0.001 0.38 ,0.001 0.40 ,0.001 0.29 ,0.001
Total cholesterol 0.12 ,0.001 0.07 0.108 0.13 0.004 0.18 ,0.001 0.06 0.159
LDL-cholesterol 0.12 ,0.001 0.09 0.040 0.10 0.027 0.16 0.002 0.08 0.045
HDL-cholesterol 20.18 ,0.001 20.08 0.080 20.18 ,0.001 20.25 ,0.001 20.13 0.001
Triglycerides 0.31 ,0.001 0.17 ,0.001 0.35 ,0.001 0.39 ,0.001 0.24 ,0.001
CRP 0.18 ,0.001 0.10 0.027 0.14 0.002 0.19 ,0.001 0.16 ,0.001
IL-6 0.11 ,0.001 0.06 0.159 0.08 0.054 0.11 0.034 0.11 0.006
aCorrelation coefficients were calculated after adjustment for age and sex.
bCorrelation coefficients were calculated after adjustment for age only.
doi:10.1371/journal.pone.0024815.t003
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Odds Ratios (95% CI)
Q1
(,5.70)
Q2
(5.70–6.75)
Q3
(6.75–7.83)
Q4
($7.83) P for trend
Metabolic syndrome 65/252 83/253 119/253 145/253
Model 1 1 1.42 (0.96–2.09) 2.54 (1.74–3.71) 3.66 (2.51–5.36) ,0.001
Model 2 1 1.43 (0.96–2.12) 2.54 (1.73–3.72) 3.71 (2.53–5.46) ,0.001
Model 3 1 1.23 (0.75–2.00) 2.33 (1.43–3.80) 2.53 (1.55–4.14) ,0.001
Model 4 1 1.25 (0.76–2.06) 2.22 (1.35–3.65) 2.41 (1.46–3.97) ,0.001
Model 5 1 1.19 (0.77–1.82) 1.86 (1.22–2.82) 1.85 (1.21–2.85) 0.001
Model 6 1 1.16 (0.75–1.79) 1.81 (1.18–2.75) 1.75 (1.13–2.70) 0.003
Central obesity 98/252 125/253 133/253 162/253
Model 1 1 1.51 (1.06–2.16) 1.71 (1.20–2.44) 2.75 (1.91–3.95) ,0.001
Model 2 1 1.47 (1.03–2.11) 1.66 (1.16–2.38) 2.72 (1.88–3.93) ,0.001
Model 3 1 1.07 (0.55–2.11) 1.04 (0.53–2.04) 1.29 (0.64–2.58) 0.505
Model 4 1 1.11 (0.56–2.21) 0.99 (0.50–1.96) 1.24 (0.61–2.51) 0.617
Model 5 1 1.26 (0.85–1.86) 1.16 (0.78–1.71) 1.39 (0.92–2.10) 0.160
Model 6 1 1.24 (0.84–1.84) 1.13 (0.77–1.68) 1.35 (0.89–2.04) 0.216
Elevated blood pressure 90/252 87/253 111/253 125/253
Model 1 1 0.96 (0.66–1.40) 1.40 (0.96–2.02) 1.59 (1.10–2.30) 0.004
Model 2 1 0.99 (0.67–1.45) 1.43 (0.98–2.08) 1.66 (1.14–2.41) 0.002
Model 3 1 0.84 (0.56–1.27) 1.11 (0.74–1.67) 1.04 (0.69–1.57) 0.598
Model 4 1 0.85 (0.56–1.29) 1.07 (0.71–1.62) 1.00 (0.66–1.51) 0.768
Model 5 1 0.87 (0.59–1.30) 1.15 (0.78–1.69) 1.07 (0.72–1.60) 0.515
Model 6 1 0.86 (0.58–1.28) 1.13 (0.76–1.66) 1.03 (0.69–1.55) 0.624
Hyperglycemia 144/252 143/253 165/253 184/253
Model 1 1 0.95 (0.67–1.36) 1.36 (0.94–1.95) 1.89 (1.29–2.75) ,0.001
Model 2 1 0.96 (0.67–1.38) 1.37 (0.95–1.97) 1.88 (1.28–2.76) ,0.001
Model 3 1 0.90 (0.62–1.29) 1.21 (0.84–1.77) 1.54 (1.04–2.28) 0.014
Model 4 1 0.86 (0.60–1.25) 1.16 (0.80–1.70) 1.49 (1.00–2.22) 0.022
Model 5 1 0.92 (0.64–1.32) 1.23 (0.85–1.79) 1.54 (1.03–2.29) 0.017
Model 6 1 0.89 (0.62–1.28) 1.16 (0.80–1.69) 1.38 (0.92–2.07) 0.067
Hypertriglyceridemia 38/252 57/253 85/253 124/253
Model 1 1 1.74 (1.09–2.76) 3.01 (1.93–4.68) 5.42 (3.51–8.37) ,0.001
Model 2 1 1.77 (1.11–2.82) 3.07 (1.96–4.79) 5.55 (3.58–8.61) ,0.001
Model 3 1 1.60 (0.99–2.59) 2.53 (1.60–4.02) 4.15 (2.64–6.54) ,0.001
Model 4 1 1.61 (0.99–2.61) 2.45 (1.53–3.91) 4.07 (2.57–6.45) ,0.001
Model 5 1 1.54 (0.96–2.49) 2.40 (1.52–3.80) 3.48 (2.20–5.51) ,0.001
Model 6 1 1.52 (0.94–2.46) 2.34 (1.47–3.71) 3.32 (2.09–5.28) ,0.001
Low HDL cholesterol 69/252 91/253 92/253 117/253
Model 1 1 1.51 (1.03–2.21) 1.58 (1.08–2.31) 2.51 (1.72–3.67) ,0.001
Model 2 1 1.53 (1.04–2.25) 1.58 (1.07–2.32) 2.56 (1.75–3.76) ,0.001
Model 3 1 1.39 (0.93–2.07) 1.29 (0.87–1.93) 1.88 (1.26–2.81) 0.003
Model 4 1 1.42 (0.95–2.12) 1.30 (0.87–1.95) 1.87 (1.25–2.79) 0.004
Model 5 1 1.38 (0.92–2.05) 1.24 (0.83–1.86) 1.63 (1.08–2.45) 0.034
Model 6 1 1.38 (0.93–2.06) 1.26 (0.85–1.87) 1.67 (1.11–2.52) 0.024
Model 1, adjusted for age and sex;
Model 2, further adjusted for smoking, alcohol drinking, physical activity, educational attainment and family history of chronic diseases based on model 1;
Model 3, further adjusted for BMI based on model 2;
Model 4, further adjusted for inflammatory markers (CRP and IL-6) based on model 3.
Model 5, further adjusted for insulin based on model 2;
Model 6, further adjusted for HOMA-IR based on model 2.
doi:10.1371/journal.pone.0024815.t004
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effects of most potential confounders by employing strict exclusion
criteria and recruiting a relatively large sample of apparently
healthy adults with both sexes. A randomized study with a
sufficiently large sample will further decrease the potential role of
residual confounding. Certainly, our results should be examined in
longitudinal studies to establish the causal relationship between
amylin and metabolic syndrome. Whether increased amylin could
serve as a useful biomarker or intervention target in clinical settings
for predicting and controlling metabolic diseases should be
determined prospectively among different populations.
In summary, our findings suggest that elevated circulating
amylin is strongly associated with MetS, independent of
established risk factors including obesity, inflammatory markers
and insulin resistance in apparently healthy Chinese. Our results
also provide novel insights into the potential role(s) of amylin in the
development of metabolic diseases.
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Figure 2. Adjusted odds ratios for MetS according to amylin quartiles, obesity status (A), and quartiles of CRP (B), IL-6 (C), insulin
(D), HOMA-IR (E). Adjusted for age, sex, smoking, alcohol drinking, physical activity, educational attainment and family history of chronic diseases.
A: Modified MetS was defined as having two or more components of the MetS without central obesity. Normal weight: 18#BMI,24 kg/m
2;
overweight/obese: BMI$24.0 kg/m
2. P=0.105 for interaction of amylin and BMI, P=0.443 for interaction of amylin and CRP; P=0.448 for interaction
of amylin and IL-6; P=0.375 for interaction of amylin and insulin; P=0.397 for interaction of amylin and HOMA-IR.
doi:10.1371/journal.pone.0024815.g002
Figure 1. The severity of MetS according to amylin quartiles.
P,0.001 for trend.
doi:10.1371/journal.pone.0024815.g001
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